Synairgen (LON:SNG) Shares Down 2.4% – Should You Sell?

Synairgen plc (LON:SNG)’s share price traded down 2.4% during trading on Tuesday . The stock traded as low as GBX 2.05 ($0.03) and last traded at GBX 2.19 ($0.03). 1,204,007 shares traded hands during trading, a decline of 10% from the average session volume of 1,343,892 shares. The stock had previously closed at GBX 2.25 ($0.03).

Synairgen Trading Down 16.9 %

The company has a quick ratio of 6.35, a current ratio of 6.77 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of £3.68 million, a P/E ratio of -60.93 and a beta of -2.23. The company has a fifty day simple moving average of GBX 3.65 and a two-hundred day simple moving average of GBX 3.98.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).